» Articles » PMID: 17718101

Multiple-drug Intolerance Syndrome: Clinical Findings and Usefulness of Challenge Tests

Overview
Date 2007 Aug 28
PMID 17718101
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple-drug intolerance syndrome (MDIS) is characterized by adverse reactions to several classes of chemically unrelated drugs.

Objective: To analyze all patients with a history of adverse reactions to at least 3 drugs at the Allergy Unit of Policlinico Gemelli in a 6-year period to better characterize patients with MDIS and to find safe alternative drugs.

Methods: We studied 480 patients (aged >16 years) with a history of adverse reactions to at least 3 unrelated drugs and with negative allergy test results. Patients who had experienced mild adverse reactions that remitted spontaneously underwent challenge tests without any premedication (group A). Patients with a clinical history of moderate reactions received sodium cromolyn, 500 mg, before the challenge (group B). Patients with a clinical history of severe reactions or undergoing parenteral challenges were given an antihistamine 30 minutes before the challenge (group C).

Results: In group A, 491 tolerance challenge tests were performed: 414 had negative results and 77 had positive results. In group B, 1,077 tolerance challenge tests were performed: 956 had negative results and 121 had positive results. In group C, 240 tolerance challenge tests were performed: 214 had negative results and 26 had positive results. Comparing the tolerance of alternative drugs in groups A and B, groups A and C, and groups B and C, no significant results were observed (P = .24, .14, and .44, respectively).

Conclusions: Patients with MDIS can tolerate alternative drugs. Premedication with sodium cromolyn or oral H1-antihistamines may be useful in preventing adverse reactions.

Citing Articles

Why Pharmacovigilance of Non-steroidal Anti-inflammatory Drugs is Important in India?.

Dash S, Singh P, Bajwa N, Choudhury A, Bisht P, Sharma R Endocr Metab Immune Disord Drug Targets. 2023; 24(7):731-748.

PMID: 37855282 DOI: 10.2174/0118715303247469230926092404.


Primary ciliary dyskinesia associated with multiple drug intolerance syndrome: a case report.

Guirat Dhouib N, Lachtar F, Ben Abdallah F, Dahech D, Guirat R, Ghozzi H Tunis Med. 2023; 100(12):877-880.

PMID: 37551537 PMC: 10485822.


Characterization, epidemiology and risk factors of multiple drug allergy syndrome and multiple drug intolerance syndrome: A systematic review.

Jagpal P, AlShareef S, Marriott J, Krishna M Clin Transl Allergy. 2022; 12(8):e12190.

PMID: 36017174 PMC: 9395947. DOI: 10.1002/clt2.12190.


Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity.

Behera S, Das S, Chengappa K, Xavier A, Selvarajan S Curr Clin Pharmacol. 2018; 14(2):84-90.

PMID: 30417793 PMC: 7011677. DOI: 10.2174/1574884713666181112125714.


Multiple drug intolerance syndrome and multiple drug allergy syndrome: Epidemiology and associations with anxiety and depression.

Blumenthal K, Li Y, Acker W, Chang Y, Banerji A, Ghaznavi S Allergy. 2018; 73(10):2012-2023.

PMID: 29574787 PMC: 6157012. DOI: 10.1111/all.13440.